Search results for: Claude Schmitt
Filter search results
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…Garau, Claude Schmitt, Alastair Kent, Adam Hutchings. (2013) A Pilot study of multi-criteria decision analysis for valuing orphan medicines. Value in Health. doi:10.1016/j.jval.2013.10.002 [An earlier version is available on this website as Research…
The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
12 October 2022
…| News and features | News | NICE. [online] Available at: https://www.nice.org.uk/news/article/nice-reaches-important-milestone-in… [Accessed 30 Jun. 2022]. Rothery, C., Woods, B., Schmitt, L., Claxton, K., Palmer, S. and Sculpher, M., 2018….
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…Pricing and reimbursement policies in Spain: current and future trends; Overview Contributors: Claude Le Pen, J-Mattias von der Schulenburg, Martina Garau, Adrian Towse, Livio Garattini, Joan Costa-i-Font, Patricia Danzon 2007…
Valuing Orphan Medicines Using Multi-Criteria Decision Analysis
7 May 2013
…registered users. Download: Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A. Multi-criteria decision analysis to value orphan medicines. Research Paper 13/03. London: Office of Health…
OHE at Priorities 2016: Valuing Health at the End of Life and MCDA for Priority Setting
19 September 2016
…N., Grainger, D., Lee, E.K. and Oortwijn, W., 2016. “New Age” Decision Making in HTA: Is It Applicable in Asia? OHE Briefing Sussex, J., Rollet, P., Garau, M., Schmitt, C.,…
Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
20 December 2016
…& Sussex, J. 2011. Incorporating Multiple Criteria in HTA: Methods and Processes. In: OHE (ed.) OHE Monograph. Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. & Hutchings, A….
Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions: Opportunities, Challenges and Unresolved Questions
18 May 2017
…J., 2011. Incorporating Multiple Criteria in HTA: Methods and Processes. London: Office of Health Economics. Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. & Hutchings, A., 2013. A…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…Garau, M., Schmitt, C., Kent, A. and Hutchings, A., (2013). A pilot study of multicriteria decision analysis for valuing orphan medicines. Value in Health, 16(8), pp.1163-1169. Devlin N., Sussex J.:…